0001563665 false --12-31 Q1 Yes Yes http://fasb.org/us-gaap/2023#UsefulLifeTermOfLeaseMember 0001563665 2023-01-01 2023-03-31 0001563665 2023-05-08 0001563665 2023-03-31 0001563665 2022-12-31 0001563665 2022-01-01 2022-03-31 0001563665 BSTG:SeriesEConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001563665 us-gaap:CommonStockMember 2022-12-31 0001563665 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001563665 us-gaap:RetainedEarningsMember 2022-12-31 0001563665 BSTG:SeriesEConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001563665 us-gaap:CommonStockMember 2021-12-31 0001563665 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001563665 us-gaap:RetainedEarningsMember 2021-12-31 0001563665 2021-12-31 0001563665 BSTG:SeriesEConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001563665 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001563665 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001563665 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001563665 BSTG:SeriesEConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001563665 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001563665 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001563665 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001563665 BSTG:SeriesEConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001563665 us-gaap:CommonStockMember 2023-03-31 0001563665 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001563665 us-gaap:RetainedEarningsMember 2023-03-31 0001563665 BSTG:SeriesEConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001563665 us-gaap:CommonStockMember 2022-03-31 0001563665 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001563665 us-gaap:RetainedEarningsMember 2022-03-31 0001563665 2022-03-31 0001563665 BSTG:HarvardBiosciencePlanMember 2013-10-01 2013-10-31 0001563665 us-gaap:SubsequentEventMember 2023-04-01 2023-05-12 0001563665 srt:MinimumMember BSTG:FurnitureMachineryAndEquipmentComputerEquipmentAndSoftwareMember 2023-03-31 0001563665 srt:MaximumMember BSTG:FurnitureMachineryAndEquipmentComputerEquipmentAndSoftwareMember 2023-03-31 0001563665 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-03-31 0001563665 us-gaap:PrivatePlacementMember 2023-03-31 2023-03-31 0001563665 us-gaap:PrivatePlacementMember 2023-03-31 0001563665 BSTG:HarvardBioscienceIncMember BSTG:SeriesEConvertiblePreferredStockMember 2022-04-28 2022-04-28 0001563665 BSTG:HarvardBioscienceIncMember BSTG:SeriesEConvertiblePreferredStockMember 2022-06-10 2022-06-10 0001563665 BSTG:SeriesEConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001563665 BSTG:SeriesEConvertiblePreferredStockMember 2023-03-31 0001563665 BSTG:UndesignatedPreferredStockMember 2023-03-31 0001563665 us-gaap:SeriesBPreferredStockMember 2023-03-31 0001563665 us-gaap:SeriesCPreferredStockMember 2023-03-31 0001563665 us-gaap:SeriesDPreferredStockMember 2023-03-31 0001563665 us-gaap:SeriesEPreferredStockMember 2023-03-31 0001563665 BSTG:BiostageAmendedAndRestateEquityIncentivePlanMember 2023-01-01 2023-03-31 0001563665 BSTG:BiostageAmendedAndRestateEquityIncentivePlanMember 2023-03-31 0001563665 us-gaap:PerformanceSharesMember 2023-03-31 0001563665 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001563665 us-gaap:EmployeeStockOptionMember BSTG:Biostage2013EquityIncentivePlanMember 2022-12-31 0001563665 us-gaap:EmployeeStockOptionMember BSTG:Biostage2013EquityIncentivePlanMember 2022-01-01 2022-12-31 0001563665 us-gaap:EmployeeStockOptionMember BSTG:Biostage2013EquityIncentivePlanMember 2023-01-01 2023-03-31 0001563665 us-gaap:EmployeeStockOptionMember BSTG:Biostage2013EquityIncentivePlanMember 2023-03-31 0001563665 BSTG:Biostage2013EquityIncentivePlanMember 2023-01-01 2023-03-31 0001563665 BSTG:Biostage2013EquityIncentivePlanMember 2022-01-01 2022-03-31 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember BSTG:Biostage2013EquityIncentivePlanMember 2023-01-01 2023-03-31 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember BSTG:Biostage2013EquityIncentivePlanMember 2022-01-01 2022-03-31 0001563665 us-gaap:SellingGeneralAndAdministrativeExpensesMember BSTG:Biostage2013EquityIncentivePlanMember 2023-01-01 2023-03-31 0001563665 us-gaap:SellingGeneralAndAdministrativeExpensesMember BSTG:Biostage2013EquityIncentivePlanMember 2022-01-01 2022-03-31 0001563665 BSTG:MedmarcMember 2022-03-03 2022-03-03 0001563665 BSTG:HarvardBioscienceInc.Member 2022-04-01 2022-06-30 0001563665 BSTG:HarvardBioscienceInc.Member 2023-01-01 2023-03-31 0001563665 BSTG:HarvardBioscienceInc.Member us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001563665 BSTG:HarvardBioscienceInc.Member BSTG:SeriesEEightPercentageConvertiblePreferredStockMember 2022-06-10 2022-06-10 0001563665 BSTG:HarvardBioscienceInc.Member BSTG:SeriesEEightPercentageConvertiblePreferredStockMember 2022-06-10 0001563665 srt:MinimumMember 2023-01-01 2023-03-31 0001563665 srt:MaximumMember 2023-01-01 2023-03-31 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001563665 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0001563665 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001563665 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001563665 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001563665 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001563665 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001563665 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-04-01 2023-04-12 0001563665 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-04-12 0001563665 us-gaap:PrivatePlacementMember us-gaap:SubsequentEventMember 2023-04-06 2023-04-06 0001563665 us-gaap:SubsequentEventMember us-gaap:SeriesEPreferredStockMember 2023-04-06 0001563665 us-gaap:SeriesEPreferredStockMember us-gaap:SubsequentEventMember 2023-04-06 2023-04-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure BSTG:Segment BSTG:item

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended March 31, 2023

 

☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from            to            

 

Commission file number 001-35853

 

BIOSTAGE, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   45-5210462
(State or Other Jurisdiction of   (IRS Employer
Incorporation or Organization)   Identification No.)

 

84 October Hill Road, Suite 11, Holliston, MA 01746
(Address of Principal Executive Offices)   (Zip Code)

 

(774) 233-7300

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ YES ☐ NO

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ YES ☐ NO

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
   
Non-accelerated filer ☒ Smaller reporting company ☒
   
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ YES ☒ NO

 

As of May 8, 2023, there were 13,882,060 shares of common stock, par value $0.01 per share, outstanding.

 

 

 

  

 

 

Biostage Inc.

Form 10-Q

For the Quarter Ended March 31, 2023

 

INDEX

 

      Page
PART I-FINANCIAL INFORMATION   3
       
Item 1. Condensed Consolidated Financial Statements   3
       
  Condensed Consolidated Balance Sheets   3
       
  Condensed Consolidated Statements of Operations (Unaudited)   4
       
  Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited)   5
       
  Condensed Consolidated Statements of Cash Flows (Unaudited)   6
       
  Notes to Unaudited Condensed Consolidated Financial Statements   7
       
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   16
       
Item 3. Quantitative and Qualitative Disclosures about Market Risk   22
       
Item 4. Controls and Procedures   22
       
PART II-OTHER INFORMATION   23
       
Item 1. Legal Proceedings   23
       
Item 1A. Risk Factors   23
       
Item 6. Exhibits   23
       
SIGNATURES   24

 

 2 

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Condensed Consolidated Financial Statements.

 

BIOSTAGE, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and par value data)

 

   March 31,   December 31, 
   2023   2022 
   (Unaudited)      
ASSETS          
Current assets:          
Cash  $3,269   $1,241 
Prepaid research and development   266    274 
Prepaid expenses and other current assets   91    79 
Total current assets   3,626    1,594 
Property, plant and equipment, net   46    49 
Right-of-use assets, net   120    147 
Deferred financing costs   544    610 
Total assets  $4,336   $2,400 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities:          
Accounts payable  $755   $682 
Accrued and other current liabilities   472    582 
Operating lease liability, current   99    99 
Total current liabilities   1,326    1,363 
Operating lease liability, net of current portion   21    48 
Total liabilities   1,347    1,411 
           
Commitments and contingencies (Note 7)   -     -  
Series E convertible preferred stock, par value $0.01 per share, 5,000 shares authorized; 4,051 and 4,180 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively   4,051    4,180 
           
Stockholders’ deficit:          
Common stock, par value $0.01 per share, 60,000,000 shares authorized; 12,716,534 and 12,174,467 issued and outstanding at March 31, 2023 and December 31, 2022, respectively   127    122 
Additional paid-in capital   84,712    79,698 
Accumulated deficit   (85,901)   (83,011)
Total stockholders’ deficit   (1,062)   (3,191)
Total liabilities and stockholders’ deficit  $4,336   $2,400 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 3 

 

 


BIOSTAGE, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except share and per share data)

 

   2023   2022 
   Three Months Ended 
   March 31, 
   2023   2022 
         
Operating expenses:          
Research and development  $509   $303 
General and administrative   2,378    1,902 
Total operating expenses   2,887    2,205 
           
Operating loss   (2,887)   (2,205)
           
Other (expense) income, net:          
Sublease income   -    29 
Other expense, net   (3)   (1)
Total other (expense) income, net   (3)   28 
           
Net loss   (2,890)   (2,177)
Less: preferred stock dividends   (80)   — 
Net loss attributable to common stockholders  $(2,970)  $(2,177)
           
Basic and diluted net loss per share  $(0.24)  $(0.20)
Weighted average common shares, basic and diluted   12,206,036    10,761,861 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 4 

 

 

BIOSTAGE, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(Unaudited)

(In thousands, except share data)

 

   Stock   Outstanding   Stock   Capital   Deficit   Deficit 
   Series E Convertible Preferred   Number of Common Shares   Common   Additional Paid-in   Accumulated   Total Stockholders’ 
   Stock   Outstanding   Stock   Capital   Deficit   Deficit 
Balance at January 1, 2023  - $4,180    12,174,467   $122   $79,698   $(83,011)  $(3,191)
Preferred stock dividends   80    —    —    (80)   —    (80)
Conversion of preferred stock for common stock   (209)   31,933    —    209    —    209 
Issuance of common stock, net of offering costs   —    510,134    5    3,045    —    3,050 
Share-based compensation expense   —    —    —    1,840    —    1,840 
Net loss -  —    —    —    —    (2,890)   (2,890)
Balance at March 31, 2023 - $4,051    12,716,534   $127   $84,712   $(85,901)  $(1,062)

 

   Series E Convertible Preferred  

Number of

Common

Shares

   Common   Additional Paid-in   Accumulated   Total Stockholders’ 
  Stock   Outstanding   Stock   Capital   Deficit   Deficit 
Balance at January 1, 2022 - $—    10,760,871   $108   $73,801   $(76,938)  $(3,029)
Share-based compensation expense   —    —    —    235    —    235 
Net loss-  —    —    —    —    (2,177)   (2,177)
Balance at March 31, 2022 - $—    10,760,871   $108   $74,036   $(79,115)  $(4,971)

 

See accompanying notes to unaudited condensed consolidated financial statements

 

 5 

 

 

BIOSTAGE, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

   2023   2022 
   Three Months Ended 
   March 31, 
   2023   2022 
OPERATING ACTIVITIES          
Net loss  $(2,890)  $(2,177)
Adjustments to reconcile net loss to net cash used in operating activities:          
Share-based compensation expense   1,840    235 
Depreciation   12    14 
Change in fair value of warrant liability   –    (2)
Deferred financing costs   66    — 
Changes in operating assets and liabilities:          
Prepaid research and development   8    — 
Prepaid expenses and other current assets   (12)   193 
Accounts payable   73    597 
Accrued and other current liabilities   (110)   621 
Net cash used in operating activities   (1,013)   (519)
           
INVESTING ACTIVITIES          
Purchases of property, plant, and equipment   (9)   — 
Net cash used in investing activities   (9)   — 
           
FINANCING ACTIVITIES          
Advance from private placement   –    3,055 
Proceeds from issuance of common stock   3,050    — 
Net cash provided by financing activities   3,050    3,055 
Net increase in cash and restricted cash   2,028    2,536 
Cash and restricted cash at the beginning of the year   1,241    1,292 
Cash and restricted cash at the end of the period  $3,269   $3,828 
           
Supplemental disclosure of non-cash activities:          
Purchases of property and equipment in accounts payable or accrued expenses  $9   $— 
Preferred stock dividends  $80   $— 
Conversion of preferred stock into common stock  $209   $— 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 6 

 

 

BIOSTAGE, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

1. Overview and Basis of Presentation

 

Overview

 

Biostage, Inc. (Biostage or the Company) is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastro-intestinal system and the airway that result from cancer, trauma or birth defects. The Company’s technology is based on our proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. The Company believes that its technology represents a next generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrificing of another of the patient’s own organs or permanent artificial implants. Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets. The Company has one business segment and does not have significant costs or assets outside the United States.

 

On October 31, 2013, Harvard Bioscience, Inc., or Harvard Bioscience, contributed its regenerative medicine business assets, plus $15 million of cash into Biostage, or the Separation. On November 1, 2013, the spin-off of the Company from Harvard Bioscience was completed. On that date, the Company became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution to Harvard Bioscience stockholders of all the shares of common stock of Biostage, or the Distribution.

 

The Company’s common stock is currently traded on the OTCQB Venture Market under the symbol “BSTG”.

 

Going Concern

 

The Company has incurred substantial operating losses since its inception, and as of March 31, 2023 had an accumulated deficit of approximately $85.9 million and will require additional financing to fund future operations. The Company expects that its operating cash on-hand as of March 31, 2023 of approximately $3.3 million and equity financing of $2.9 million in gross proceeds subsequent to March 31, 2023 will enable it to fund its operating expenses and capital expenditure requirements into the first quarter of 2024. Therefore, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.

 

The Company will need to raise additional funds to fund its operations. In the event the Company is unable to raise additional capital from outside sources before or during the first quarter of 2024, it may be forced to curtail or cease its operations.

 

Cash requirements and cash resource needs will vary significantly depending upon the timing of the financial and other resource needs that will be required to complete ongoing development, pre-clinical and clinical testing of product candidates, as well as regulatory efforts and collaborative arrangements necessary for the Company’s product candidates that are currently under development. The Company is currently seeking and will continue to seek financing from other existing and/or new investors to raise necessary funds through a combination of public or private equity offerings. The Company may also pursue debt financings, other financing mechanisms, research grants, or strategic collaborations and licensing arrangements. The Company may not be able to obtain additional financing on favorable terms, if at all.

 

The Company’s operations will be adversely affected if it is unable to raise or obtain needed funding and may materially affect the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern and therefore, the condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classifications of liabilities that may result from the outcome of this uncertainty.

 

 7 

 

 

2. Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements

 

Summary of Significant Accounting Policies

 

The accounting policies underlying the accompanying unaudited condensed consolidated financial statements are those set forth in Note 2 to the consolidated financial statements for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K.

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of Biostage and its three wholly-owned subsidiaries, Harvard Apparatus Regenerative Technology Limited (Hong Kong), Harvard Apparatus Regenerative Technology GmbH (Germany) and Biostage Limited (UK). The functional currency for Biostage and these subsidiaries is the U.S dollar. All intercompany balances and transactions have been eliminated in consolidation.

 

Basis of Presentation

 

The condensed consolidated financial statements reflect the Company’s financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States, or U.S. GAAP.

 

Use of Estimates

 

The process of preparing condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, share-based compensation, valuation of warrant liability, accrued expenses and the valuation allowance for deferred income taxes. Actual results could differ from those estimates.

 

Property, Plant and Equipment

 

Property, plant and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows:

 

Leasehold improvements 

Shorter of
expected useful
life or lease term

 
Furniture, machinery and equipment, computer equipment and software   3-7 years 

 

Maintenance and repairs are charged to expense as incurred, while any additions or improvements are capitalized.

 

Net Loss Per Share

 

Basic net loss per share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, warrants to purchase common stock and stock options are considered to be common stock equivalents, but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented.

 

 8 

 

 

Unaudited Interim Financial Information

 

The accompanying interim condensed consolidated balance sheet as of March 31, 2023, condensed consolidated interim statements of operations, stockholders’ deficit and cash flows for the three months ended March 31, 2023 and 2022 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared in accordance with GAAP on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2023, its condensed consolidated results of operations, stockholders’ deficit and cash flows for the three months ended March 31, 2023 and 2022. The financial data and other information disclosed in these notes related to the three months ended March 31, 2023 and 2022 are unaudited. The results for the three months ended March 31, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023, any other interim periods or any future year or period.

 

Recently Adopted Accounting Pronouncements

 

Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s condensed consolidated financial statements upon adoption.

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-12). The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The Company adopted this standard on January 1, 2023, and the adoption of ASU 2016-13 did not have a material impact on its consolidated financial statements.

 

3. Accrued and Other Current Liabilities

 

Accrued and other current liabilities consist of the following:

 

   March 31,   December 31, 
   2023   2022 
   (in thousands) 
Advisory costs  $337   $300 
Legal costs   -    135 
Audit services   44    80 
Payroll   83    55 
Other liabilities   8    12 
Total accrued and other current liabilities  $472   $582 

 

4. Capital Stock

 

Private Placement

 

On March 31, 2023, the Company entered into Securities Purchase Agreements, each a Purchase Agreement, with new and existing investors, the Investors, pursuant to which the Investors agreed to purchase in a private placement an aggregate of 510,134 shares of common stock for the aggregate purchase price of approximately $3.1 million with a purchase price per unit of $6.00, the Private Placement.

 

The Company had 1,113,622 warrants to purchase common stock outstanding as of March 31, 2023 with a weighted-average exercise price of $4.69.

 

5. Series E Convertible Preferred Stock

 

On April 28, 2022, the Company entered into a Preferred Issuance Agreement, or PIA, with Harvard Bioscience, Inc., or HBIO, dated as of April 27, 2022. Pursuant to the PIA, the Company and HBIO agreed that once HBIO has paid at least $4.0 million in certain settlement and related legal expenses, to satisfy the Company’s indemnification obligations with respect thereto, in lieu of paying cash, the Company would issue senior convertible preferred stock to HBIO that will contain terms as described in the PIA.

 

 9 

 

 

On June 10, 2022, following the execution of a subscription agreement and HBIO providing evidence of payment of the requisite $4.0 million amount, the Company issued HBIO 4,000 shares of Series E Convertible Preferred Stock, or Series E Preferred, at a price of $1,000 per share to satisfy the Company’s related indemnification obligations pertaining to the $4.0 million, in lieu of paying cash. As of March 31, 2023, there were 4,051 shares of Series E Preferred outstanding and includes approximately $251,000 accrued as dividends payable as shares of Series E Preferred.

 

The rights, preferences, and privileges of the Series E Preferred stock were as follows as of March 31, 2023:

 

Dividends: Payable quarterly in additional shares of Series E Preferred stock at a rate of 8% per annum, accrued daily and compounded quarterly.

 

Voting Rights: The holders of Series E Preferred stock shall have no voting rights except as required by applicable law.

 

Consent Rights: As long as any shares of Series E Preferred stock are outstanding, the holder of the Series E Preferred stock has certain consent rights with respect to the Company (a) incurring any indebtedness for borrowed money or any guaranty therefore in excess of $500,000 individually or in the aggregate, (b) entering into certain new material related party transactions, and (c) authorizing or issuing any securities unless the same ranks junior to the Series E Preferred.

 

Liquidation Rights: The Series E Preferred stock shall, with respect to dividends and distributions upon any voluntary or involuntary liquidation, dissolution or winding up of the Company or a deemed liquidation event or otherwise, rank prior to all classes of Common Stock of the Company and, except for any Preferred Stock that may be pari passu or senior to the Series E Preferred Stock, in each case, if consented to by the holder of the Series E Preferred, all other classes or series of Preferred Stock of the Company, whether currently existing or hereafter created.

 

Mandatory Conversion: Each share of Series E Preferred stock will automatically convert into shares of Common Stock of the Company upon the earlier to occur of the Company’s offering that includes common stock (whether private placement or public offering) that coincides with its uplisting onto NASDAQ, its initial public offering pursuant to a Registration Statement on Form S-1 that includes common stock following the issuance of the Series E Preferred, or its initial private placement that includes common stock following the issuance of the Series E Preferred in the event the gross proceeds of such private placement are at least $4,000,000. In such instance, each share of Series E Preferred will convert into that number of shares of Common Stock determined by dividing (i) the stated value plus all accrued and unpaid dividends, by (ii) the lowest price per share of common stock purchased in the applicable offering by the Company which triggered the mandatory conversion, or if such price cannot be reliably determined, a reasonably calculated price per common share determined by the Company and the holder.

 

Optional Conversion: Each share of Series E Preferred stock will also be subject to optional conversion by the holder thereof into that number of shares of Common Stock determined by dividing (i) the stated value plus all accrued and unpaid dividends, by (ii) a price per share equal to the average of the volume weighted average trading prices of the Common Stock for the most recently completed sixty (60) consecutive trading days prior to the date of determination.

 

The conversion options require settlement through a variable number of shares. Based on the mechanic of the conversion options, it is not possible to determine if the Company would be able to satisfy the settlement of the conversion option. Shareholder approval would be required to increase the number of authorized common shares. This action would be outside of the control of the Company. Accordingly, it is presumed that cash settlement would be required. Management has determined that based upon this analysis, temporary equity classification would be appropriate.

 

 10 

 

 

Other than Series E Preferred shares, there were no other shares of any of the other classes of preferred stock outstanding as of March 31, 2023. Authorized shares for each preferred stock class are as follows:

 

   Authorized 
Undesignated preferred stock   979,000 
Series B convertible preferred stock   1,000,000 
Series C convertible preferred stock   4,000 
Series D convertible preferred stock   12,000 
Series E convertible preferred stock   5,000 

 

6. Share-Based Compensation

 

Biostage Amended and Restated Equity Incentive Plan

 

The Company maintains the Amended and Restated Equity Incentive Plan (the Plan) for the benefit of certain officers, employees, non-employee directors, and other key persons (including consultants and advisory board members). All options and awards granted under the Plan consist of the Company’s shares of common stock. The Company’s policy is to issue stock available from its registered but unissued stock pool through its transfer agent to satisfy stock option exercises and vesting of the restricted stock units. The vesting period for awards is generally four years and the contractual life is ten years. Canceled and forfeited options and awards are available to be reissued under the Plan.

 

The Company’s Plan has 5,098,000 authorized shares to be issued under the Plan. There were 2,275,128 shares available for issuance as of March 31, 2023.

 

The following table summarizes information concerning options outstanding and exercisable:

 

       Weighted-average   Weighted-average contractual life   Aggregate intrinsic value 
   Amount   exercise price   (years)   (in thousands) 
Outstanding at December 31, 2022   2,516,924   $            3.95    7.68   $6,917 
Granted   858,470    6.03           
Canceled / forfeited   (573,209)   6.16           
Outstanding at March 31, 2023   2,802,185    4.14    7.69    9,389 
Options exercisable   1,941,834    4.63    7.63    6,446 
Options vested and expected to vest   2,696,248    4.18    7.69    9,028 

 

The Company’s outstanding stock options include 430,579 performance-based awards that have vesting provisions subject to the achievement of certain business milestones. Total unrecognized compensation expense for the remaining performance-based awards is approximately $1.2 million. No expense has been recognized for these awards as of March 31, 2023 given that the milestone achievements for these awards have not yet been deemed probable for accounting purposes.

 

Aggregate intrinsic value for outstanding options and exercisable options as of March 31, 2023, was approximately $9.4 million and $6.4 million, respectively, based on the Company’s closing stock price of $6.45 per share as of March 31, 2023. As of March 31, 2023, unrecognized compensation cost related to unvested non-performance-based awards amounted to $0.9 million, which will be recognized over a weighted-average period of 2.39 years.

 

 11 

 

 

The Company uses the Black-Scholes option pricing model to value its stock options. The weighted average assumptions for valuing options granted during the three months ended March 31, 2023 and March 31, 2022 were as follows:

 

   Three Months Ended March 31, 
   2023   2022 
Risk-free interest rate   4.10%   1.77%
Expected volatility   126.6%   122.06%
Expected term (in years)   5.7 years    6.0 years 
Expected dividend yield   —%   —%

 

The Company recorded share-based compensation expense in the following expense categories of its condensed consolidated statements of operations:

 

   Three months ended 
   March 31, 
   2023   2022 
   (In thousands) 
Research and development  $62   $60 
General and administrative   1,778    175 
Total stock-based compensation  $1,840   $235 

 

7. Commitments and Contingencies

 

On April 14, 2017, representatives for the estate of an individual plaintiff filed a wrongful death complaint with the Suffolk Superior Court, in the County of Suffolk, Massachusetts, against the Company and other defendants, including Harvard Bioscience, Inc., or HBIO, the former parent of the Company that spun off the Company in 2013, as well as another third party. The complaint sought payment for an unspecified amount of damages and alleged that the plaintiff sustained terminal injuries allegedly caused by products provided by certain of the named defendants and utilized in connection with surgeries performed by third parties in Europe in 2012 and 2013. This lawsuit related to the Company’s first-generation trachea scaffold technology for which the Company discontinued development in 2014, and not to the Company’s current Biostage Esophageal Implant.

 

On April 27, 2022, the Company and HBIO executed a settlement with the plaintiffs (the “Settlement”), which resolves all claims relating to the litigation. The Settlement resulted in the dismissal with prejudice of the wrongful death claim, and neither the Company nor HBIO admit any fault or liability in connection with the claim. The Settlement also resolved any and all claims by and between the parties and the Company’s product liability insurance carriers, which resulted in the dismissal with prejudice of all claims asserted by or against those carriers, the Company and HBIO.

 

In relation to the litigation, the Company paid approximately $5.9 million of aggregate costs related to the lawsuit, of which 100% has been paid as of December 31, 2022. This aggregate amount included the cost of legal and related costs incurred by the Company, which consisted of attorneys’ fees and advisor and specialist costs as part of its defense in this matter. On March 3, 2022, the Company received a cash payment of approximately $0.1 million from Medmarc, the Company’s insurance carrier. This amount represented a reimbursement of previously incurred legal costs and was recorded as a reduction to general and administrative expenses during the three months ended March 31, 2022.

 

12

 

 

With respect to such $5.9 million of costs described above, the Company was required to either pay such costs directly or indemnify HBIO as to such amounts it incurs. Of such amounts, the Company anticipated that HBIO would pay an aggregate amount of $4.0 million by the end of the second quarter of 2022. With respect to the indemnification obligation of the Company to HBIO pertaining to such costs, the Company and HBIO entered into a Preferred Issuance Agreement dated as of April 27, 2022, or the “PIA”. In connection with the PIA, the Company and HBIO agreed that once HBIO had paid at least $4.0 million in such costs, to satisfy the Company’s indemnification obligations with respect thereto, in lieu of paying cash, the Company would issue senior 8% convertible preferred stock to HBIO that will contain terms as described in the PIA, including the term sheet attached thereto. On June 10, 2022, following the execution of a subscription agreement and HBIO providing evidence of payment of the requisite $4.0 million amount, the Company issued HBIO 4,000 shares of Series E 8% Convertible Preferred Stock at a price of $1,000 per share to satisfy the Company’s related indemnification obligations aggregating $4.0 million, which included the accrual for contingency of $3.3 million and approximately $0.8 million of legal and related costs paid on behalf of the Company by HBIO previously included in accrued expenses.

 

From time to time, the Company may be involved in various claims and legal proceedings arising in the ordinary course of business. Other than the above matter, there are no such matters pending that the Company expects to be material in relation to its business, financial condition, results of operations, or cash flows.

 

8. Leases

 

The Company leases laboratory and office space and certain equipment with remaining terms ranging from 1 to 2 years.

 

The laboratory and office space arrangement is under a sublease that was renewed in December of 2022 and currently extends through May 31, 2024. This lease automatically renews annually for one-year periods unless the Company or the counterparty provides a notice of termination within one hundred and eighty days prior to May 31st of each year.

 

On January 5, 2022, the Company executed a four-month sublease agreement for certain laboratory and office space at its Holliston, Massachusetts facility. The Company further extended the sublease agreement on a month-to-month basis until August 31, 2022 when the other party vacated the premises. For the three months ended March 31, 2022, the Company recorded sublease income of approximately $29,000 relating to this agreement.

 

All of the Company’s leases qualify as operating leases. The following table summarizes the presentation of the Company’s operating leases in its condensed consolidated balance sheets:

 

      March 31,   December 31, 
   Balance Sheet Classification  2023   2022 
            
Assets:             
Operating lease assets  Right-of-use asset, net  $120   $147 
Liabilities:             
Current portion of operating lease liabilities  Current portion of operating lease liabilities   99    99 
Operating lease liabilities, net of current portion  Operating lease liabilities, net of current portion   21    48 
Total operating lease liabilities     $120   $147 

 

13

 

 

The Company recorded operating lease expense in the following categories in its condensed consolidated statements of operations:

 

   Three months ended March 31, 
   2023   2022 
   (In thousands) 
Research and development  $19   $19 
General and administrative   11    11 
Total  $30   $30 

 

Cash paid included in the computation of the operating lease assets and lease liabilities during the three months ended March 31, 2023 and 2022 amounted to approximately $30,000 for each quarterly period.

 

The weighted average remaining lease term and weighted average discount rate of the Company’s operating leases are as follows:

 

   As of March 31, 
   2023   2022 
Remaining lease term (in years)   1.24    1.37 
Discount rate   14.76%   9.18%

 

The minimum lease payments for the next two years are expected to be as follows:

 

   March 31, 2023 
   As of 
   March 31, 2023 
   (in thousands) 
2023  $82 
2024   50 
Total lease payments   132 
Less: imputed interest   (12)
Present value of operating lease liabilities  $120 

 

9. Net Loss Per Share

 

   2023   2022 
   Three months ended March 31, 
   2023   2022 
   (in thousands, except shares and per share data) 
Net loss  $(2,890)  $(2,177)
Preferred stock dividends   (80)   — 
Net loss attributable to common stockholders  $(2,970)  $(2,177)
           
Basic and diluted weighted average common shares outstanding   12,206,036    10,761,861 
           
Basic and diluted net loss per share attributable to common stockholders  $(0.24)  $(0.20)

 

14

 

 

The following potential common shares were excluded from the calculation of diluted net loss per share attributable to common stockholders for the three months ended March 31, 2023 and 2022 because including them would have had an anti-dilutive effect:

 

   Three months ended March 31, 
   2023   2022 
Options to purchase common stock   2,802,185    2,402,603 
Warrants to purchase common stock   1,113,622    1,583,786 
Total   3,915,807    3,986,389 

 

10. Income Taxes

 

The Company did not record a federal or state income tax provision or benefit for the three months ended March 31, 2023 and 2022, respectively, due to the expected loss before income taxes to be incurred for the years ended December 31, 2023 and 2022, as well as the Company’s continued maintenance of a full valuation allowance against its net deferred tax assets.

 

11. Subsequent Events

 

The Company performed a review of events subsequent to the balance sheet through the date the financial statements were issued and determined that there were no such events requiring recognition or disclosure in the financial statements except as disclosed below.

 

Subsequent to March 31, 2023 through April 12, 2023, the Company entered into Securities Purchase Agreements, each a Purchase Agreement, with new and existing investors, the Investors, pursuant to which the Investors agreed to purchase in a private placement an aggregate of 490,833 shares of common stock for the aggregate purchase price of approximately $2.9 million with a purchase price per unit of $6.00, the Private Placement.

 

In connection with the Private Placement, as of April 6, 2023 the Company had received $4.0 million in aggregate proceeds in such Private Placement. As a result, all of the Company’s outstanding Series E Preferred Stock and related accrued dividends were converted into shares of common stock at a conversion price of $6.00 per share. The conversion resulted in 674,693 shares of common stock being issued to the holder of the Series E Preferred Stock. Following such conversion, there are no shares of Series E Preferred Stock outstanding.

 

15

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Forward Looking Statements

 

This Quarterly Report on Form 10-Q contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). The forward-looking statements are principally, but not exclusively, contained in “Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements include, but are not limited to, statements about management’s confidence or expectations and our plans, objectives, expectations and intentions that are not historical facts and the potential impact of COVID-19 on our business and operations. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “goals,” “sees,” “estimates,” “projects,” “predicts,” “intends,” “think,” “potential,” “objectives,” “optimistic,” “strategy,” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Factors that may cause our actual results to differ materially from those in the forward-looking statements include our ability to access debt and equity markets and raise additional funds when needed; the success of our collaborations, clinical trials and pre-clinical development efforts and programs, which success may not be achieved on a timely basis or at all; our ability to obtain and maintain regulatory approval for our implant products, bioreactors, scaffolds and other devices we pursue, including for the esophagus or airway, which approvals may not be obtained on a timely basis or at all; the number of patients who can be treated with our products; the amount and timing of costs associated with our development of implant products, bioreactors, scaffolds and other devices; our failure to comply with regulations and any changes in regulations; unpredictable difficulties or delays in the development of new technology; our collaborators or other third parties we contract with, including with respect to conducting any clinical trial or pre-clinical development efforts, not devoting sufficient time and resources to successfully carry out their duties or meet expected deadlines; our ability to attract and retain qualified personnel and key employees and retain senior management; potential liability exposure with respect to our products; the availability and price of acceptable raw materials and components from third-party suppliers; difficulties in obtaining or retaining the management and other human resource competencies that we need to achieve our business objectives; increased competition in the field of regenerative medicine and bioengineering, and the financial resources of our competitors; our ability to obtain and maintain intellectual property protection for our device and product candidates; our inability to implement our growth strategy; the control our principal stockholders can exert based on holding a majority of voting power; plus factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2023 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

 

Biostage, Inc. is referred to herein as “we,” “our,” “us”, and “the Company”.

 

Business Overview

 

We are a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastro-intestinal system and the airway that result from cancer, trauma or birth defects. Our technology is based on our proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. We believe that our technology represents a next generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrificing of another of the patient’s own organs or permanent artificial implants.

 

16

 

 

We conducted the world’s first successful regeneration of the esophagus in a cancer patient in August 2017. This surgery was performed by Dr. Dennis Wigle, Chair of Thoracic Surgery at the Mayo Clinic in a patient with esophageal cancer. The results were published in the Journal of Thoracic Oncology Clinical and Research Reports in August 2021. The procedure demonstrated that using Biostage’s technology, we were able to successfully regenerate esophageal tissue, including the mucosal lining, to restore the integrity, continuity and functionality of the esophageal tube. This successful first-in-human experience, plus the research we have performed on 45 pigs, led the U.S. Food and Drug Administration (“FDA”) to approve our 10-patient combined phase 1 and phase 2 clinical trial. This combination trial will measure both safety and efficacy in the patient population.

 

We were incorporated and commenced operations on November 1, 2013 as a result of a spin-off from Harvard Bioscience, Inc., or Harvard Bioscience. On that date, we became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution of all the shares of common stock of Biostage to Harvard Bioscience stockholders.

 

We have also formed a subsidiary in Hong Kong, Harvard Apparatus Regenerative Technology Limited, as we continue to assess the market and regulatory approval pathway in China as to our implant products. We are not certain at this time as to which market, including U.S. or China for example, may provide the most viable initial pathway for regulatory approval to a commercial product. This will depend on a number of factors, including the approval and development processes, related costs, ability to raise capital and the terms and conditions thereof, as well as the ongoing impact of the COVID-19 pandemic, among other factors. Any development and capital raising efforts in China may include a joint venture in relation to our Hong Kong subsidiary, and would also involve a number of commercial variables, including rights and obligations pertaining to licensing, development, and financing, among others. Our failure to receive or obtain such clearances or approvals on a timely basis or at all, whether that be in the U.S., China or otherwise, would have an adverse effect on our results of operations.

 

Since our incorporation, we have devoted substantially all of our resources to developing our programs, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. To date, we have financed our operations with proceeds from the sales of common stock and preferred stock. In December 2017, we sold the inventory and rights to manufacture and sell research-only versions of our bioreactors to Harvard Bioscience. We did not recognize any revenues during the quarters ended March 31, 2023 and 2022.

 

We have contracted with IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, as the contract research organization (CRO) to manage our first clinical trial. We plan to start patient enrollment in this clinical trial in the second quarter of 2023. Our product candidates are currently in development and have not yet received regulatory approval for sale anywhere in the world.

 

Financial Condition and Need for Additional Funds

 

We expect to continue to incur operating losses and negative cash flows from operations for 2023 and in future years.

 

Operating Losses and Cash Requirements

 

We have incurred substantial operating losses since our inception, and as of March 31, 2023 had an accumulated deficit of approximately $85.9 million and will require additional financing to fund future operations. We expect that our operating cash on-hand as of March 31, 2023 of approximately $3.3 million and equity financing of $2.9 million in gross proceeds subsequent to March 31, 2023 will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2024. We expect to continue to incur operating losses and negative cash flows from operations for 2023 and in future years. Therefore, as disclosed in Note 1 to our Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q, these conditions raise substantial doubt about our ability to continue as a going concern.

 

We will need to raise additional funds to fund our operations. In the event we do not raise additional capital from outside sources before or during the first quarter of 2024, we may be forced to curtail or cease our operations.

 

17

 

 

Cash requirements and cash resource needs will vary significantly depending upon the timing of the financial and other resource needs that will be required to complete ongoing development, pre-clinical and clinical testing of product candidates, as well as regulatory efforts and collaborative arrangements necessary for our product candidates that are currently under development. We are currently seeking and will continue to seek financings from other existing and/or new investors to raise necessary funds through a combination of public or private equity offerings. We may also pursue debt financings, other financing mechanisms, research grants, or strategic collaborations and licensing arrangements. We may not be able to obtain additional financing on favorable terms, if at all.

 

Our operations will be adversely affected if we are unable to raise or obtain needed funding and may materially affect our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared assuming that we will continue as a going concern and therefore, the condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classifications of liabilities that may result from the outcome of this uncertainty.

 

Components of Operating Loss

 

Research and development expense. Research and development expense consists of salaries and related expenses, including share-based compensation, for personnel and contracted consultants and various materials and other costs to develop our new products, primarily: synthetic scaffolds, including investigation and development of materials and investigation and optimization of cellularization, as well as studies of cells and cell behavior. Other research and development expenses include the costs of outside service providers and material costs for prototype and test units and outside laboratories and testing facilities performing cell growth and materials experiments, as well as the costs of all other preclinical research and testing including animal studies and expenses related to potential patents. We expense research and development costs as incurred.

 

General and administrative expense. General and administrative expense consists primarily of salaries and other related expenses, including share-based compensation, for personnel in executive, accounting, information technology and human resources roles. Other costs include professional fees for legal and accounting services, insurance, investor relations and facility costs.

 

Sublease income. On January 5, 2022, we executed a four-month sublease agreement for certain laboratory and office space at its Holliston, Massachusetts facility. We further extended the sublease agreement to a month-to-month basis until August 31, 2022 when the other party vacated the premises. We have no sublease agreements generating sublease income as of March 31, 2023.

 

Other (expense) income, net. Other (expense) income, net, consists primarily of the changes in fair value of our warrant liability from the change in the fair value of common stock warrants classified as liability awards during the three months ended March 31, 2022. We previously used the Black-Scholes pricing model to value the related warrant liability. In February of 2022, the underlying common stock warrants expired unexercised.

 

Critical Accounting Policies and Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States, or. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ materially from these estimates under different assumptions or conditions.

 

While our significant accounting policies are discussed in more detail in Note 2 to our Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.

 

18

 

 

Share-based Compensation

 

We account for our share-based compensation in accordance with the fair value recognition provisions of current authoritative guidance. Share-based awards, including stock options, are measured at fair value as of the grant date and recognized as expense over the requisite service period (generally the vesting period), which we have elected to amortize on a straight-line basis. Expense on share-based awards for which vesting is performance or milestone based is recognized on a straight-line basis from the date when we determine the achievement of the milestone is probable to the vesting/milestone achievement date. Since share-based compensation expense is based on awards ultimately expected to vest, it has been reduced by an estimate for future forfeitures. Until December 31, 2022, we estimated forfeitures at the time of grant and would revise our estimate, if necessary, in subsequent periods. As of January 1, 2023, we account for forfeitures as they occur. We estimate the fair value of options granted using the Black-Scholes option valuation model. Significant judgment is required in determining the proper assumptions used in this model. The assumptions used include the risk-free interest rate, expected term, expected volatility, and expected dividend yield. We base our assumptions on historical data when available or, when not available, on a peer group of companies. However, these assumptions consist of estimates of future market conditions, which are inherently uncertain and subject to our judgment, and therefore any changes in assumptions could significantly impact the future grant date fair value of share-based awards.

 

Warrant Liability

 

Most of the warrants to purchase shares of our common stock have been classified on our condensed consolidated balance sheets as equity. We classify warrants as a liability in our condensed consolidated balance sheets if the warrant is a free-standing financial instrument that may require us to transfer cash consideration upon exercise and that cash transfer event would be out of our control. Such a “liability warrant” is initially recorded at fair value on the date of grant using the Black-Scholes model, net of issuance costs, and it is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in fair value of the warrants is recognized as a component of other expense in the condensed consolidated statements of operations. The warrants classified as a liability expired unexercised during the three months ended March 31, 2022 and the remaining liability on the expiration date of approximately $2,000 was recognized as other income.

 

Results of Operations

 

The following table summarizes the results of our operations for the three months ended March 31, 2023 and 2022 (in thousands):

 

   Three months ended March 31,   Change 2023 vs. 2022 
   2023   2022   Change   % 
Operating expenses                    
Research and development  $509   $303   $206    68%
General and administrative   2,378    1,902    476    25%
Total operating expenses   2,887    2,205    682    31%
                     
Other expense                    
Sublease income   -    29    (29)   nm%
Other expense, net   (3)   (1)   (2)   200%
Total other expense, net   (3)   (28)   (31)   (111)%
Net loss  $(2,890)  $(2,177)  $(713)   33%

 

nm = not meaningful

 

19

 

 

Comparison of the three months ended March 31, 2023 and March 31, 2022

 

Research and Development Expense

 

Research and development expense increased approximately $0.2 million, or 68%, to approximately $0.5 million for the three months ended March 31, 2023 as compared to approximately $0.3 million for the three months ended March 31, 2022. This increase was primarily due to higher headcount and preclinical trial activities.

 

General and Administrative Expense

 

General and administrative expense increased approximately $0.5 million, or 25%, to approximately $2.4 million for the three months ended March 31, 2023 as compared to approximately $1.9 million for the three months ended March 31, 2022. This increase was primarily due to share-based compensation expense of $1.5 million from the vesting of performance based awards in the first quarter of 2023, increased headcount related costs of approximately $0.1 million and an increase of approximately $0.1 million for supporting our ongoing public company requirements offset by the reduced legal and related costs of approximately $1.2 million relating to the completion of litigation for a wrongful death complaint and related matters more fully described in Note 7 to our condensed consolidated financial statements.

 

Sublease income

 

On January 5, 2022, we executed a four-month sublease agreement for certain laboratory and office space at our Holliston, Massachusetts facility. We further extended the sublease agreement on a month-to-month basis until August 31, 2022 when the other party vacated the premises. For the three months ended March 31, 2022, we recorded sublease income of approximately $29,000 relating to this agreement. We have no sublease agreements generating sublease income as of March 31, 2023.

 

Other (expense) income, net

 

During the three months ended March 31, 2023, we recorded interest expense of approximately $3,000 on insurance installment payments.

 

During the three months ended March 31, 2022, we recorded a gain on expiration of the common share warrants of approximately $2,000 in other expense, net as they expired unexercised in February 2022.

 

Liquidity and Capital Resources

 

Sources of liquidity. We have incurred operating losses since inception, and as of March 31, 2023, we had an accumulated deficit of approximately $85.9 million. We are currently investing significant resources in the development and commercialization of our product candidates for use by clinicians and researchers in the fields of regenerative medicine and bioengineering. As a result, we expect to incur operating losses and negative operating cash flows for the foreseeable future.

 

20

 

 

The following table sets forth the primary uses of cash for the three months ended March 31, 2023 and 2022 (in thousands):

 

   Three Months Ended March 31, 
   2023   2022 
Net cash used in operating activities  $(1,013)  $(519)
Net cash used by investing activities  $(9)  $— 
Net cash provided by financing activities  $3,050   $3,055 

 

Comparison of three months Ended March 31, 2023 and 2022

 

Operating activities. Net cash used in operating activities of approximately $1.0 million for the three months ended March 31, 2023 was due primarily to our net loss of approximately $2.9 million offset by adjustments for non-cash items of approximately $1.9 million due to non-cash expenses for share-based compensation and depreciation.

 

Net cash used in operating activities of approximately $0.5 million for the three months ended March 31, 2022 was due primarily to our net loss of approximately $2.2 million offset by adjustments for non-cash items of approximately $0.3 million due to non-cash expenses including share-based compensation, depreciation and the change in fair value of our warrant liability and an approximately $1.4 million increase in cash from changes in working capital due to the timing of payments for prepaid expenses and increases in accounts payable and accrued expenses.

 

Investing activities. Net cash used in investing activities for the three months ended March 31, 2023 and 2022 totaled approximately $9,000 and zero, respectively, and represented purchases of property, plant and equipment.

 

Financing activities. Net cash generated from financing activities during the three months ended March 31, 2023 of approximately $3.1 million consisted of net proceeds received from a private placement transaction that resulted in the issuance of 510,134 shares of our common stock at a purchase price of $6.00 per share to a group of investors.

 

In February and March of 2022, we received cash of approximately $3.1 million from a group of new and existing investors pertaining to a private placement transaction which closed in May 2022. These funds had remained the respective investor’s property and were held in escrow by us in a separate account until the execution of the common stock purchase agreements which occurred on May 12, 2022.

 

Off-Balance Sheet Arrangements

 

We do not have any material off-balance sheet arrangements as of March 31, 2023.

 

Other Information

 

None.

 

21

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

The Company is a smaller reporting company and is not required to provide this information pursuant to Item 305(e), Regulation S-K.

 

Item 4. Controls and Procedures.

 

This Report includes the certifications of our principal executive officer and our principal financial and accounting officer required by Rule 13a-14 of the Exchange Act. See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer, Director, and Chairman, who is our principal executive officer, and our Chief Financial Officer, who is our principal financial and accounting officer, to allow timely decisions regarding required disclosures.

 

In connection with the preparation of this Quarterly Report on Form 10-Q, our management, under the supervision and with the participation of our principal executive officer and our principal financial and accounting officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2023. Based upon the evaluation described above, our principal executive officer and our principal financial and accounting officer have concluded that they believe our disclosure controls and procedures were effective as of the end of the period covered by this report, in providing reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial and accounting officer, to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

 

Changes in Internal Control over Financial Reporting

 

Our management, with the participation of our principal executive officer and our principal financial and accounting officer, has evaluated whether any change in our internal control over financial accounting and reporting occurred during the quarter ended March 31, 2023. During the period covered by this report, we have concluded that there were no changes during the fiscal quarter in our internal control over financial reporting, as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act, which have materially affected, or are reasonably likely to materially affect, our internal control over financial accounting and reporting.

 

22

 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time, we may be involved in various claims and legal proceedings arising in the ordinary course of business. Other than the civil lawsuit described in Item 3 of Part I of our Annual Report on Form 10-K filed with the SEC on March 30, 2023 and in our Form 8-K filed with the SEC on April 27, 2022, there are no such matters pending that we expect to be material in relation to our business, financial condition, and results of operations or cash flows.

 

Item 1A. Risk Factors

 

To our knowledge and except to the extent additional factual information disclosed in this Quarterly Report on Form 10-Q relates to such risk factors, there have been no material changes in the risk factors described in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on March 30, 2023.

 

Item 6. Exhibits

 

Exhibit Index

    
10.1   Employment Agreement between Biostage, Inc. and Junli He (previously filed as an exhibit to Form 8-K, filed on March 14, 2023, and incorporated herein by reference).
     
10.2   Form of Securities Purchase Agreement (previously filed as an exhibit to Form 8-K, filed on April 6, 2023, and incorporated herein by reference).
     
31.1+   Certification of Chief Executive Officer, Director, and Chairman of Biostage, Inc., pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2+   Certification of Chief Financial Officer of Biostage, Inc., pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1*   Certification of Chief Executive Officer, Director, and Chairman of Biostage, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2*   Certification of Chief Financial Officer of Biostage, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS   Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Labels Linkbase Document
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
Exhibit 104   Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

+Filed herewith.

 

* This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

 

23

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by undersigned thereunto duly authorized.

 

Date: May 12, 2023

 

  BIOSTAGE, INC.
     
  By: /s/ Junli He
  Name: Junli He
  Title: Chief Executive Officer, Director, and Chairman (principal executive officer)
     
  By: /s/ Joseph L.Damasio Jr.
  Name:  Joseph L. Damasio Jr.
  Title:

Chief Financial Officer

(principal financial officer)

 

24

NYLI Healthy Hearts ETF (AMEX:HART)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more NYLI Healthy Hearts ETF Charts.
NYLI Healthy Hearts ETF (AMEX:HART)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more NYLI Healthy Hearts ETF Charts.